top of page
LATEST NEWS
Two Years In, Elevidys Shows Functional Benefit in Older Boys With Duchenne
Boys with Duchenne who received Elevidys between ages 8 and 12 kept more motor function over two years than matched untreated boys, Sarepta reported at the World Muscle Society Congress. Here is what the data show, and what they don't.
5 hours ago5 min read


No, CRISPR Hasn't Cured Down Syndrome. Here's What the Viral Study Really Showed
A viral post claims scientists can now remove the extra chromosome behind Down syndrome. The 2025 Mie University study is real, but it was done in lab-grown cells, not babies, and it is far from a treatment. Here is the myth vs. fact.
3 days ago4 min read


One CRISPR Infusion Kept Cholesterol and Triglycerides Down for a Full Year
One-year data for CTX310, a single-infusion CRISPR therapy that switches off ANGPTL3 in the liver, showed LDL cholesterol down 53% and triglycerides down 48% at the top dose, with no treatment-related serious side effects.
3 days ago4 min read


LEARN MORE
LEARN MORE

GENE TECH TIMES
The Future Has Arrived


Two Years In, Elevidys Shows Functional Benefit in Older Boys With Duchenne
Boys with Duchenne who received Elevidys between ages 8 and 12 kept more motor function over two years than matched untreated boys, Sarepta reported at the World Muscle Society Congress. Here is what the data show, and what they don't.
5 hours ago
bottom of page


